Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  01:00 2022-12-02 am EST
3967.00 JPY   -1.64%
11/23Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
AQ
11/23Takeda Says US FDA Grants Priority Review to Its Dengue Vaccine Candidate
MT
11/22Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limited Issues Notice of Redemption to the Holders of 4.400% Senior Notes Due 2023

09/27/2022 | 08:01pm EST

Takeda Pharmaceutical Company Limited announced that it will redeem $1,000,000,000 of the total $1,500,000,000 outstanding aggregate principal amount of the Notes on October 27, 2022 at the Redemption Price calculated in the manner set below. The Notes were issued pursuant to an indenture dated as of November 26, 2018, by and between the Company and U.S. Bank National Association, as successor trustee to MUFG Union Bank, N.A., as trustee. Capitalized terms used and not otherwise defined herein have the meanings given thereto in the Indenture.

This redemption is being made at the option of the Company pursuant to Section 10.1 of the Indenture. This notice of redemption is being given pursuant to Sections 1.6 and 10.5 of the Indenture in accordance with the terms of the Notes.


ę S&P Capital IQ 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
11/23Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Gra..
AQ
11/23Takeda Says US FDA Grants Priority Review to Its Dengue Vaccine Candidate
MT
11/22Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Gra..
BU
11/22Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration A..
CI
11/18Takeda - Phase 3 Trial of ICLUSIG Met Primary Endpoint in Newly-Diagnosed Ph+ ALL a Set..
AQ
11/17Takeda Pharmaceutical Says Phase 3 Leukemia Drug Trial Meets Main Endpoint
MT
11/17Phase 3 Trial of ICLUSIG« (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, ..
BU
11/17Takeda Announces Phase 3 Trial of Iclusig Met Primary Endpoint in Newly-Diagnosed Ph+ A..
CI
11/16Takeda and Discovery Education Partner on New Initiative Focusing on Health Equity
AQ
11/15Big pharma not doing enough to improve drug access - analysis
RE
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 894 B 28 774 M 28 774 M
Net income 2023 324 B 2 393 M 2 393 M
Net Debt 2023 2 714 B 20 053 M 20 053 M
P/E ratio 2023 18,9x
Yield 2023 4,54%
Capitalization 6 167 B 45 571 M 45 571 M
EV / Sales 2023 2,28x
EV / Sales 2024 2,25x
Nbr of Employees 47 347
Free-Float 96,5%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 967,00 JPY
Average target price 4 529,38 JPY
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Masami Iijima Chairman
Andrew S. Plump Director, President-Research & Development
Michael E. Mendelsohn Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED26.46%45 571
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY34.07%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774